## REVION HEALTH CARE (UK) LIMITED





## INTER OFFICE MEMORANDUM

U0000063



STRICTLY CONFIDENTIAL

TO

Dr P A Harris

DATE: February 25, 1986

FROM

Mr R B Christie

REF: RBC/EB/10167

SUBJECT :

SERO-CONVERSION OF PATIENT FOLLOWING INFUSION OF FACTORATE Y69402

COPIES TO :

As part of my follow up, being conducted at the request of the DHSS, on all patients who received treatment with Factorate Heat Treated Y69402, the following patient, treated by Dr Whitmore of Lewisham Hospital, London has been reported as a sero-conversion.

You will recall that Factorate Heat Treated batch Y69402 was identified as one batch originating from the pool of plasma that contained a donation from a donor who subsequently developed AIDS.

Details of the patient are as follows. (His name has been withheld on the grounds of confidentiality).

The patient is a mild haemophiliac who had received no Factor VIII concentrate or blood products for a long period (more than 1 year) prior to a test for HTLV-III antibody on 17/1/85. This test was negative.

On 5/2/85 he received two bottles (540 units) of Heat Treated Factorate Y69402. This was the only treatment of any sort that was given and he has received no treatment since.

On 6/5/85 he was re-tested for HTLV-III antibody and proved to be positive. He was re-tested on 4/11/85 and the positive result was confirmed.

The patient remained physically well. His T4 T8 ratio was normal, his T-rosette test was 16% slightly abnormal. He has no lymphadenopathy.

Although to quote Dr Whitmore, the patient is "a somewhat strange character", he is not in any known risk category for AIDS except, of course, haemophilia treatment.

Dr Whitmore feels that this may be an immune response to dead virus but cannot, of course, confirm this.

It is interesting to note that a further patient of Dr Whitmore who was HTLV-III negative and was treated with Y69402 on 25/2/85 following an accident, remained negative at two subsequent re-tests on 4/4/85 and 9/8/85. This patient had received NON-Heat Treated Factor VIII concentrate in 1970 but had been managed on cryoprecipitate and DDAVP since that time.

GRO-C

R B Christie

REV 48